Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.17/2680 |
Resumo: | Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials. |
id |
RCAP_74879813f06c92b60d723bbb4ac28971 |
---|---|
oai_identifier_str |
oai:repositorio.chlc.min-saude.pt:10400.17/2680 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical UsefulnessHCC MEDBelimumabBiologic TherapyImmunosuppressive AgentsSystemic Lupus ErythematosusSystemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.SAGE PublicationsRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEGuerreiro Castro, SIsenberg, D2017-04-19T15:12:26Z2017-032017-03-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/2680engTher Adv Musculoskelet Dis. 2017 Mar;9(3):75-8510.1177/1759720X17690474info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-10T09:39:06Zoai:repositorio.chlc.min-saude.pt:10400.17/2680Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:20:01.098342Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness |
title |
Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness |
spellingShingle |
Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness Guerreiro Castro, S HCC MED Belimumab Biologic Therapy Immunosuppressive Agents Systemic Lupus Erythematosus |
title_short |
Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness |
title_full |
Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness |
title_fullStr |
Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness |
title_full_unstemmed |
Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness |
title_sort |
Belimumab in Systemic Lupus Erythematosus (SLE): Evidence-To-Date and Clinical Usefulness |
author |
Guerreiro Castro, S |
author_facet |
Guerreiro Castro, S Isenberg, D |
author_role |
author |
author2 |
Isenberg, D |
author2_role |
author |
dc.contributor.none.fl_str_mv |
Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE |
dc.contributor.author.fl_str_mv |
Guerreiro Castro, S Isenberg, D |
dc.subject.por.fl_str_mv |
HCC MED Belimumab Biologic Therapy Immunosuppressive Agents Systemic Lupus Erythematosus |
topic |
HCC MED Belimumab Biologic Therapy Immunosuppressive Agents Systemic Lupus Erythematosus |
description |
Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-04-19T15:12:26Z 2017-03 2017-03-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.17/2680 |
url |
http://hdl.handle.net/10400.17/2680 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Ther Adv Musculoskelet Dis. 2017 Mar;9(3):75-85 10.1177/1759720X17690474 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
SAGE Publications |
publisher.none.fl_str_mv |
SAGE Publications |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131296931250176 |